Anti-HCV antibodies: A battle for breadth and potency
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Potent and broadly neutralizing antibodies (NAbs) are important for clearance of RNA virus infections. However, NAbs generated in response to RNA viruses exhibit diverse profiles of potency and breadth. In this study, we conducted a comparative analysis of NAbs targeting HIV, hepatitis C virus (HCV), SARS-CoV-2, and influenza based on their potency, measured by IC50 values, and breadth, assessed through the genetic diversity of the viruses neutralized by the NAbs. Our results reveal that while anti-HCV NAbs show a high breadth of neutralization, they are less potent and demonstrate inconsistent potency across different virus variants. These findings highlight the challenges in eliciting broad and potent antibody responses, which are essential for the development of effective vaccine strategies against HCV.
